Table 2

Management and outcome data of patients with definite endocarditis according to study period

VariablePre-ET
(n=101)
Post-ET
(n=95)
P valuePost-ET
(Pre-ET involvement)*
Complications
 Immunological phenomena11 (10.9)11 (11.6)1.009 (81.8)
 Acute stroke22 (21.8)19 (20.0)0.8611 (57.9)
 Other emboli38 (37.6)31 (32.6)0.5516 (51.6)
 Congestive cardiac failure17 (16.8)15 (15.8)1.004 (26.7)
 Uncontrolled sepsis18 (17.8)27 (28.4)0.098 (29.6)
 Valvular abscess11 (10.9)13 (13.6)0.668 (61.5)
 Renal failure†11 (10.9)10 (10.5)1.005 (50.0)
Investigations
 Time to first TTE (days)7.8±11.64.8±7.90.04
 Time to TOE following TTE (days)4.9±4.13.5±3.10.02
 Number of patients undergoing TOE69 (68.3)77 (81.1)0.05
Management
 Time to IE-specific antibiotics4.0±4.02.5±3.20.004
 Duration of stay29.2+15.923.9±15.60.02
Management strategy
 Medical21 (20.8)24 (25.3)0.55
 Medical (surgical turndown)6 (5.9)8 (8.4)
 Surgical74 (73.3)63 (66.3)
Mortality
 In-hospital17 (17.5)12 (12.6)0.42
 1 year31 (30.7)22 (23.2)0.25
  • Data shown as means±SD or number (percentage).

  • *Complications occurring before the involvement of the ET during the post-ET period.

  • †Renal failure requiring renal replacement therapy.

  • ET, endocarditis team; IE, infective endocarditis; TOE, transoesophageal echocardiogram; TTE, transthoracic echocardiogram.